Vaccines & Vaccination Open Access,
Journal Year:
2024,
Volume and Issue:
9(2), P. 1 - 6
Published: Aug. 14, 2024
Vaccines
have
long
been
used
globally
as
preventive
and
therapeutic
agents
against
various
diseases.
Global
necessity
of
coseffective,
edible
functional
food
based
vaccine
development
has
led
the
scientists
search
for
multiple
that
would
act
either
directly
or
adjuvant.
In
this
article,
potentiality
medicinal
mushrooms
mushroom
bio-components’
adjuvants
direct
vaccines
critically
reviewed.
Outcomes
present
article
be
immense
importance
to
immunologists,
health-care
professionals
policy
makers
worldwide.
Journal of Agriculture and Food Research,
Journal Year:
2024,
Volume and Issue:
16, P. 101189 - 101189
Published: May 6, 2024
Probiotics,
the
health-promoting
members
of
gut
microbiota,
have
been
shown
to
enhance
mucosal
and
systemic
immunity,
stimulate
cytokines,
chemokines,
antibodies,
regulate
T-cell
activity.
On
other
hand,
traditional
adjuvants
like
alum
limitations,
researchers
are
exploring
probiotics
as
a
new
generation
vaccine
treat
immune
disorders
effectiveness.
For
instance,
studies
show
that
probiotic
strains
Lactobacillus
rhamnosus
GG
(LGG)
can
improve
response
vaccines
against
rotavirus,
SARS-CoV-2,
influenza.
Besides,
delivered
through
various
routes
(oral
ocular)
could
offer
broader
protection
wider
range
infections.
not
only
boost
system
but
also
trigger
production
anti-inflammatory
cytokines
regulatory
cells,
they
potential
in
cancer
immunotherapy.
Studies
demonstrate
LGG
Bifidobacterium
longum
increase
efficacy
by
promoting
T
cell
infiltration,
thereby
inhibiting
tumor
growth.
Additionally,
suggest
specific
L.
SL42
casei
might
be
beneficial
for
cow's
milk
allergies.
In
line
with
this,
research
on
use
peanut
allergies
shows
promise.
However,
there
is
need
more
understand
mechanisms,
identify
optimal
strains,
determine
timing
duration
administration
clinical
outcomes.
This
review
aimed
shed
light
impact
immunomodulatory
immunogenic
agents
immunizations,
well
their
infectious
diseases,
allergies,
suppression.
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(2), P. 201 - 201
Published: Feb. 2, 2024
The
underdevelopment
of
adjuvant
discovery
and
diversity,
compared
to
core
vaccine
technology,
is
evident.
On
the
other
hand,
antibiotic
resistance
on
list
top
ten
threats
global
health.
Immunomodulatory
peptides
that
target
a
pathogen
modulate
immune
system
simultaneously
are
promising
for
development
preventive
therapeutic
molecules.
Since
investigating
innate
immunity
in
insects
has
led
prominent
achievements
human
immunology,
such
as
toll-like
receptor
(TLR)
discovery,
we
used
capacity
immunomodulatory
arthropods
with
concomitant
antimicrobial
or
antitumor
activity.
An
SVM-based
machine
learning
classifier
identified
short
sequences
encrypted
643
from
55
foe-to-friend
arthropods.
critical
features
involved
efficacy
safety
were
calculated.
Finally,
76
safe
immunomodulators
identified.
Then,
molecular
docking
simulation
studies
defined
most
optimal
peptide
ligands
among
all
cell-surface
TLRs.
SPalf2-453
crab
cell-penetrating
immunoadjuvant
antiviral
properties.
interacts
TLR1/2
heterodimer.
SBsib-711
blackfly
TLR4/MD2
ligand
cancer
immunoadjuvant.
In
addition,
binds
CD47
PD-L1
tumor
cells,
which
applicable
immunotherapy
checkpoint
inhibitor.
MRh4-679
shrimp
broad-spectrum
universal
putative
Th1/Th2-balanced
response.
We
also
implemented
pathway
enrichment
analysis
define
fingerprints
immunological
signatures
further
vitro
vivo
immunogenicity
reactogenicity
measurements.
Conclusively,
combinatorial
learning,
docking,
studies,
well
systems
biology,
open
new
opportunity
multifunctional
prophylactic
lead
peptides.
European journal of medical research,
Journal Year:
2025,
Volume and Issue:
30(1)
Published: Jan. 16, 2025
Patients
with
end
stage
renal
disease
(ESRD)
undergoing
hemodialysis
are
at
increased
risk
for
infection
and
impaired
vaccination
responses.
We
analyzed
overlap
influencing
factors
of
responses
against
severe
acute
respiratory
syndrome
corona
virus
2
(SARS-CoV-2)
Hepatitis
B
(HBV).
SARS-CoV-2
HBV
response
was
assessed
in
a
cohort
German
ESRD
patients.
Anti-HBs-
anti-S-IgG
were
by
ELISA.
Demographic
clinical
data
extracted
from
files.
Sixty-four
patients
complete
information
on
included.
More
than
one-third
(35.4%)
non-responders
upon
identified.
Unresponsiveness
after
poor
showed
strong
overlap,
overall,
70.3%
classified
into
concordant
HBV/SARS
groups.
non-responsiveness,
but
not
post-vaccination
immunity
associated
obesity,
while
age.
Our
findings
confirm
previous
reports
show
that
humoral
display
this
vulnerable
patient
group.
These
results
may
help
to
adapt
strategies
highly
population.
Clinical
Trial
Registry,
DRKS00021152.
Frontiers in Biomaterials Science,
Journal Year:
2025,
Volume and Issue:
4
Published: Feb. 12, 2025
Immunotherapy
has
emerged
as
a
powerful
approach
in
treating
various
diseases,
yet
its
success
often
hinges
on
the
efficacy
of
adjuvants,
agents
that
boost
immune
responses
to
therapeutic
targets.
Traditional
adjuvants
have
offered
foundational
support
but
may
fall
short
achieving
specificity
and
potency
required
for
advanced
therapies.
This
review
highlights
new
generation
poised
address
these
limitations.
We
explore
range
innovative
agents,
including
non-inflammatory
nucleic
acid
bacterial
derivatives,
synthetic
molecules,
which
are
redefining
role
immunotherapy.
These
emerging
hold
promise
enhancing
while
tailoring
therapies
specific
disease
contexts,
from
cancer
infectious
diseases.
By
examining
applications
potential
this
aims
provide
comprehensive
understanding
how
they
can
advance
immunotherapy
levels
precision.
Through
development
novel
stands
achieve
more
targeted
sustained
impacts,
paving
way
improved
outcomes
patient
care.
Immuno,
Journal Year:
2025,
Volume and Issue:
5(1), P. 12 - 12
Published: March 14, 2025
Hepatitis
B
virus
(HBV)
infection
is
a
major
public
health
risk.
Despite
the
introduction
of
successful
vaccines,
which
are
normally
single
adjuvanted,
there
still
some
drawbacks,
including
non-responsiveness
in
certain
groups,
short
durability
immunity,
inadequate
protection,
and
need
for
additional
doses
to
be
addressed.
This
study
aimed
develop
an
optimized
combination
Cytosine-phosphate-Guanine
Oligonucleotides
(CPG-ODN2395,
CPG-ODN-18281-2
23
mer)
calcium
phosphate,
assess
its
immunogenicity
toxicity
when
co-administrated
with
commercial
HBV
vaccine
(BEVAC,
containing
aluminum
hydroxide)
in-house
hydroxide-adjuvanted
HBs
purified
antigen
Balb/c
mice.
Tail
blood
was
collected
from
vaccinated
mice
on
days
14
28
post-immunization
determine
antibody
secretion
level
using
enzyme-linked
immunosorbent
assay
(ELISA).
The
Tumor
Necrosis
Factor
(TNF-a)
interleukin-6
(IL-6)
cytokine
expression
levels
were
assessed
through
real-time
PCR,
safety
profile
checked
biochemical
hematological
analysis.
Our
results
showed
that
CPG-ODN2395,
CPG-ODN
18281-2
mer,
CAP
significantly
enhanced
IgG
(p
<
0.0001),
also
significant
increase
IL-6
0.0001).
evaluations
revealed
no
adverse
impact
liver
kidney
function,
normal
ALT,
AST,
urea,
creatinine
0.55).
Hematological
assessments
stable
parameters
across
all
groups.
concludes
combining
CpG
ODNs
phosphate
adjuvants
hepatitis
vaccinations
has
potential
enhance
stronger
immunological
response
than
adjuvants.
These
highlight
promise
this
innovative
adjuvant
system,
necessitating
more
research
clinical
environments
effectiveness
sustained
protection
against
HBV.
